3 1 form3_keim.htm MAY 21, 2002 Form 3 Keim
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES		 OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden
hours per response. . . . 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
1.  Name and Address of Reporting Person*

     Keim         Richard
     (Last)         (First)         (Middle)

     200 Park Avenue, Suite 3900
           (Street)

     New York         NY         10166
     (City)             (State)         (Zip)

 2.  Date of Event
     Requiring Statement
     (Month/Day/Year)

     May 21, 2002		 4.  Issuer Name and Ticker Symbol

    Derma Sciences, Inc.     DSCI
3.  IRS Identification
     Number of Reporting
     Person, if an entity
      (voluntary)		 5.  Relationship of Reporting Person(s) to Issuer
            (Check all applicable)

       X    Director                                   X    10% Owner
              Officer (give title below)              Other (specify below)

____________________________
 6.  If Amendment, Date of
      Original (Month/Day/Year)
7.  Individual or Joint/Group
     Filing(Check Applicable Line)

         Form filed by One Reporting Person
    X   Form filed by More than One
             Reporting Person
Table I — Non-Derivative Securities Beneficially Owned
1.  Title of Security
     (Instr. 4)		 2.  Amount of Securities
     Beneficially Owned
      (Instr. 4)		 3.  Ownership
    Form: Direct
    (D) or Indirect
    (I)  (Instr. 5)		 4.  Nature of Indirect Beneficial Ownership
    (Instr. 5)
common stock 631,875   I Owned by Kensington Partners L.P. (Note 1)
common stock 130,625   I Owned by Bald Eagle Fund Ltd. (Note 1)
common stock 28,000   I Owned by Peter Orthwein Managed Account (Note 2)
common stock 100,000   I Owned by Peter Orthwein Family Trust (Note 2)
    
    

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

*If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Page 1 of 3


Table II — Derivative Securities Beneficially Owned (e.g., puts, calls warrants, options, convertible securities)
1.  Title of Derivative Security
     (Instr. 4)		 2.  Date Exer-
    cisable and
     Expiration
     Date
     (Month/Day/Year)		 3.  Title and Amount of
     Securities Underlying
     Derivitive Security
     (Instr. 4)		 4.  Conversion
     or Exercise
     Price of
     Derivitive
     Security		 5.  Ownership
     Form of
     Derivitive
     Securities:
     Direct (D) or
     Indirect (I)
     (Instr. 5)		 6.  Nature of
     Indirect
     Beneficial Ownership
    (Instr. 5)
Date Exercisable Expiration Date  
Title		 Amount or Number of Shares
stock option (right to buy) (Note 3) 05/21/2012 common stock 90,000   $0.51   D  
Class E Warrant (right to buy) 08/25/2000 07/18/2005 common stock 361,988   $0.85   I Owned by Kensington Partners L.P. (Note 1)
Class E Warrant (right to buy) 08/25/2000 07/18/2005 common stock 78,012   $0.85   I Owned by Bald Eagle Fund Ltd. (Note 1)
               

Explanation of Responses:

(1) Richard Keim is the general partner of Kensington Partners L.P. (see attachment) and Bald Eagle Fund Ltd.

(2) Richard Keim is the discretionary manager of the Peter Orthwein Managed Account and the Peter Orthwein Family Trust.

(3) The option vested as to 60,000 shares on May 21, 2002, and will vest as to an additional 10,000 shares on May 21 of 2003, 2004, and 2005.

    /s/Richard Keim                  
**Signature of Reporting Person		 March 31, 2003
Date    
     
  KENSINGTON PARTNERS L.P.  
    /s/Richard Keim                  
By: Richard Keim, General Parnter
**Signature of Reporting Person		 March 31, 2003
Date    
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).		    
     
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form desplays a currently valid OMB Number.    

Page 2 of 3


FORM 3 ATTACHMENT: JOINT FILER INFORMATION

Designated Filer:  Richard Keim

Date of Event Requiring Statement:  May 21, 2002

Issuer Name and Ticker Symbol:  Derma Sciences, Inc.    DSCI

Joint Filer Name:  Kensington Partners L.P.

Joint Filer Address:  200 Park Avenue, Suite 3900, New York, NY 10166

Relationship of Reporting Person to Issuer:  10% owner

Page 3 of 3